ORCID as entered in ROS
https://orcid.org/0000-0002-7380-1170
Select Publications
Journal articles
, 2010, 'Quality of life in patients with advanced renal cell carcinoma treated with temsirolimus or interferon-alpha', British Journal of Cancer, 102, pp. 1456 - 1460, http://dx.doi.org/10.1038/sj.bjc.6605647
, 2009, 'Immunological's host profile for HPV and Chlamydia trachomatis, a cervical cancer cofactor', Microbes and Infection, 11, pp. 435 - 442, http://dx.doi.org/10.1016/j.micinf.2009.01.004
, 2009, 'Enhancement of the activity of phenoxodiol by cisplatin in prostate cancer cells', British Journal of Cancer, 100, pp. 649 - 655, http://dx.doi.org/10.1038/sj.bjc.6604920
, 2009, 'Analysis of PTEN and HIF-1 alpha and Correlation With Efficacy in Patients With Advanced Renal Cell Carcinoma Treated With Temsirolimus Versus Interferon-alpha', Cancer, 115, pp. 3651 - 3660
, 2009, 'Randomized phase II trial of gemcitabine and either day 1 or day 8 carboplatin for advanced non-small-cell lung cancer: Is thrombocytopenia predictable?', Asia-Pacific Journal of Clinical Oncology, 5, pp. 24 - 31
, 2008, 'Advanced osteosarcoma of the maxilla: A case report', Medicina Oral, Patologia Oral y Cirugia Bucal, 13
, 2008, 'A prospective cohort study of fatigue after adjuvant therapy for breast cancer: Association with hematologic, endocrine, and immune parameters', JOURNAL OF CLINICAL ONCOLOGY, 26, http://dx.doi.org/10.1200/jco.2008.26.15_suppl.9596
, 2008, 'Biomarker analysis and final efficacy and safety results of a phase II renal cell carcinoma trial with pazopanib (GW786034), a multi-kinase angiogenesis inhibitor', JOURNAL OF CLINICAL ONCOLOGY, 26, http://dx.doi.org/10.1200/jco.2008.26.15_suppl.5046
, 2008, 'Characterization of hyperglycemia, hypercholesterolemia, and hyperlipidemia in patients with advanced renal cell carcinoma treated with temsirolimus or interferon-α', Journal of Clinical Oncology, 26, pp. 5116 - 5116, http://dx.doi.org/10.1200/jco.2008.26.15_suppl.5116
, 2007, 'Pazopanib (GW786034) is active in metastatic renal cell carcinoma (RCC): Interim results of a phase II randomized discontinuation trial (RDT)', Journal of Clinical Oncology, 25, pp. 5031 - 5031, http://dx.doi.org/10.1200/jco.2007.25.18_suppl.5031
, 2007, '4011 POSTER Results of a phase 3, randomized study of patients with advanced renal cell carcinoma (RCC) and poor prognostic features treated with temsirolimus, interferon-a or the combination of temsirolimus + interferon-a', European Journal of Cancer Supplements, 5, pp. 282 - 283, http://dx.doi.org/10.1016/s1359-6349(07)71079-0
, 2007, 'Phase II study of carboplatin followed by sequential gemcitabine and paclitaxel as first-line treatment for advanced ovarian cancer', International Journal of Gynecological Cancer, 17, pp. 350 - 358
, 2007, 'Phase II study of gemcitabine and oxaliplatin in patients with recurrent ovarian cancer: an Australian and New Zealand Gynaecological Oncology Group study', International Journal of Gynecological Cancer, 17, pp. 359 - 366
, 2007, 'Randomized crossover study evaluating the effect of gemcitabine infusion dose rate : evidence of auto-induction of gemcitabine accumulation', Journal of Clinical Oncology, 25, pp. 5704 - 5709
, 2006, 'A phase 1 and pharmacokinetic study of gemcitabine and oxaliplatin in patients with solid tumors', Cancer Chemotherapy and Pharmacology, 58, pp. 157 - 164
, 2006, 'Concurrent-phase boost high-dose radiation therapy for non-small-cell lung cancer with or without cisplatin chemotherapy', Journal of Medical Imaging and Radiation Oncology, 50, pp. 342 - 348
, 2006, 'Phase I and pharmacokinetic study of weekly NV06 (Phenoxodioltrade mark), a novel isoflav-3-ene, in patients with advanced cancer', Cancer Chemotherapy and Pharmacology, 58, pp. 427 - 433
, 2004, 'Long-term efficacy and safety of zoledronic acid in the treatment ofskeletal metastases in patients with nonsmall cell lung carcinoma andother solid tumors - A randomized, phase III, double-blind,placebo-controlled trial', Cancer, 100, pp. 2613 - 2621
, 2003, 'Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: A phase III, double-blind, randomized trial - The zoledronic acid lung cancer and other solid tumors study group', Journal of Clinical Oncology, 21, pp. 3150 - 3157, http://dx.doi.org/10.1200/JCO.2003.04.105
, 2003, 'Erratum: GLOB-1: A prospective randomised clinical phase III trial comparing vinorelbine-cisplatin with vinorelbine-ifosfamide-cisplatin in metastatic non-small-cell lung cancer patients (Annals of Oncology) (2002) vol. 13 (1853-1861))', Annals of Oncology, 14, pp. 347, http://dx.doi.org/10.1093/annonc/mdg083
, 2001, 'Phase I trial of weekly NV-06 (Phenoxodiol (TM)), a novel isoflavonoid, in patients with advanced cancer.', CLINICAL CANCER RESEARCH, 7, pp. 3694S - 3694S, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000172121800205&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
, 2001, 'The anti osteo porotic efficacy of intravenous pamidronate in men with prostate carcinoma receiving combined androgen blockade - A double blind, randomized, placebo-controlled crossover study', CANCER, 92, pp. 1444 - 1450, http://dx.doi.org/10.1002/1097-0142(20010915)92:6<1444::AID-CNCR1468>3.0.CO;2-M
, 2001, 'The antiosteoporotic efficacy of intravenous pamidronate in men with prostate carcinoma receiving combined androgen blockade: A double blind, randomized, placebo-controlled crossover study', Cancer, 92, pp. 1444 - 1450, http://dx.doi.org/10.1002/1097-0142(20010915)92:6<1444::AID-CNCR1468>3.0.CO;2-M
, 2000, 'Phase I study of weekly vinorelbine in combination with weekly paclitaxel in adult patients with advanced refractory cancer', Cancer Investigation, 18, pp. 422 - 428
, 1997, '9-Aminocamptothecin: A topoisomerase I inhibitor with preclinical activity in prostate cancer', Clinical Cancer Research, 3, pp. 287 - 294
, 1997, 'Enhancement of paclitaxel activity against hormone-refractory prostate cancer cells in vitro and in vivo by quinacrine', British Journal of Cancer, 75, pp. 1593 - 1600, http://dx.doi.org/10.1038/bjc.1997.272
, 1996, 'Disposition and bioavailability of ceftazidime after intraperitoneal administration in patients receiving continuous ambulatory peritoneal dialysis', Journal of the American Society of Nephrology, 7, pp. 2399 - 2402
, 1995, 'Humoral hypercalcemia associated with adenocarcinoma of the rectum: A case report and review of the literature', American Journal of Clinical Oncology: Cancer Clinical Trials, 18, pp. 126 - 129, http://dx.doi.org/10.1097/00000421-199504000-00006
, 1994, 'Hypersensitivity reactions to etoposide: A report of three cases and review of the literature', American Journal of Clinical Oncology: Cancer Clinical Trials, 17, pp. 387 - 389, http://dx.doi.org/10.1097/00000421-199410000-00005
, 1993, 'Medical management of miscarriage with RU486.', Med J Aust, 159, pp. 491, https://www.ncbi.nlm.nih.gov/pubmed/8292160
, 1993, 'A cost-utility approach to the use of 5-fluorouracil and levamisole as adjuvant chemotherapy for Dukes' C colonic carcinoma [5]', Medical Journal of Australia, 158, pp. 866, http://dx.doi.org/10.5694/j.1326-5377.1993.tb137685.x
, 1992, 'Prognostic factors in ovarian cancer', Hematology/Oncology Clinics of North America, 6, pp. 761 - 781, http://dx.doi.org/10.1016/s0889-8588(18)30309-5
, 1992, 'Risk factors, epidemiology, screening, and prognostic factors in female genital cancer', Current Opinion in Oncology, 4, pp. 913 - 922, http://dx.doi.org/10.1097/00001622-199210000-00016
Conference Papers
, 2024, 'Cost-Effective Space Based Platforms for Bushfire Monitoring', in IEEE Aerospace Conference Proceedings, http://dx.doi.org/10.1109/AERO58975.2024.10521271
, 2022, 'A phase 1 dose-escalation study of the ABN401 (c-MET inhibitor) in patients with solid tumors.', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, ELECTR NETWORK, presented at
, 2022, 'A phase I dose-escalation and expansion study of HBM4003, an anti-CTLA-4 heavy chain only monoclonal antibody, in patients with advanced solid tumors', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, ELECTR NETWORK, presented at
, 2022, 'Phase 1 study of ADG126, a novel masked anti-CTLA-4 SAFEbody, that combines tumor-localized activation with strong T-reg depletion and soft ligand blocking in patients with advanced solid tumors.', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, ELECTR NETWORK, pp. E17601 - E17601, presented at
, 2021, 'A phase I dose-escalation study of HBM4003: An anti-CTLA-4 heavy-chain-only mAb', in ANNALS OF ONCOLOGY, ELSEVIER, ELECTR NETWORK, pp. S855 - S855, presented at
, 2020, 'MIR-10B AS A MARKER FOR DISSEMINATED DISEASE IN RDEB-LINKED SCCS', in ACTA DERMATO-VENEREOLOGICA, ACTA DERMATO-VENEREOLOGICA, pp. 60 - 61, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000568327600162&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
, 2020, 'MIRNA-10B MARKS AGGRESSIVE SQUAMOUS CELL CARCINOMAS IN RDEB', in ACTA DERMATO-VENEREOLOGICA, ACTA DERMATO-VENEREOLOGICA, pp. 35 - 36, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000568327600097&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
, 2019, 'A phase I dose escalation and dose expansion study of the anti-programmed cell death-1 (PD-1) antibody AK105.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at
, 2018, 'Longitudinal analysis of circulating biomarkers to monitor advanced EGFR mutated (EGFR+) non-small cell lung cancer (NSCLC)', in Annals of oncology : official journal of the European Society for Medical Oncology, pp. viii660, http://dx.doi.org/10.1093/annonc/mdy303.033
, 2018, 'Abstract B183: The WEE1 inhibitor AZD1775 in combination with chemotherapy in Asian patients with advanced solid tumors: a phase Ib study', in Molecular Cancer Therapeutics, American Association for Cancer Research (AACR), pp. B183 - B183, http://dx.doi.org/10.1158/1535-7163.targ-17-b183
, 2017, 'Docetaxel-related fatigue in men with metastatic prostate cancer: a descriptive analysis', in Supportive Care in Cancer, pp. 2871 - 2879, http://dx.doi.org/10.1007/s00520-017-3706-8
, 2017, 'Serum microRNA expression during neoadjuvant chemoradiation for rectal cancer.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at
, 2016, 'Abstract 2047: Pharmacokinetics (PK) of CRLX301, a novel nanoparticle-drug conjugate (NDC) containing the payload docetaxel, in patients with refractory solid tumors', in Cancer Research, American Association for Cancer Research (AACR), pp. 2047 - 2047, http://dx.doi.org/10.1158/1538-7445.am2016-2047
, 2016, 'A phase 1 study of CRLX301, a novel nanoparticle-drug conjugate (NDC) containing docetaxel (DOC), in patients with refractory solid tumors.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at
, 2016, 'Change in serum microRNA expression during neoadjuvant chemoradiation for rectal cancer', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, LA, New Orleans, presented at
, 2015, 'Circulating tumour cell release in the peri-operative setting during curative colorectal cancer surgery', in Annals of Oncology, Oxford University Press (OUP), Barcelona, SPAIN, presented at
, 2015, 'Impact of crossover and baseline prognostic factors on overall survival (OS) with abiraterone acetate (AA) in the COU-AA-302 final analysis.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, FL, Orlando, presented at
Filter by type
https://orcid.org/0000-0002-7380-1170